EVALUATION COMPARISON BETWEEN ASTRAZENECA AND MODERNA VACCINE’S SIDE EFFECTS AND EFFICACY AMONG INDONESIA SOCIETY BASED ON SOCIODEMOGRAPHY

GENA NAFTA ARAMINDA; DIANA LAILA RAMATILLAH

doi:10.22159/ijap.2022.v14s2.44747

Authors

GENA NAFTA ARAMINDA Pharmacy Faculty, Universitas 17 Agustus 1945 Jakarta, Jl. Sunter Permai Raya, Jakarta 14350, Indonesia
DIANA LAILA RAMATILLAH Pharmacy Faculty, Universitas 17 Agustus 1945 Jakarta, Jl. Sunter Permai Raya, Jakarta 14350, Indonesia

DOI:

https://doi.org/10.22159/ijap.2022.v14s2.44747

Keywords:

Vaccine, COVID-19, Side effects, Risk factors

Abstract

Objective: To evaluate the potential side effects and efficacy also to find the risk factors that contributed to the side effects of both vaccines in Indonesia.

Methods: This is a prospective cross-sectional study was conducted in October-December 2021; informations collection was carried out by using a standardized questionnaire and disseminated through social media. All full-dosed AstraZeneca and Moderna vaccine participants above 18 y old were included.

Results: Among 406 participants, 73.4% were female, 87.2% were in the group of 18-30 y, 80 % were Java race, and 52.6% of them had asthma. In this study, the number of participants between AstraZeneca and Moderna was almost the same (50.5% and 49.5%). The most common side effects experienced after first of AstraZeneca and Moderna vaccine were fever (65.8% and 45.3%) respectively, sore arm (77.5% and 63.6%) respectively, headache (52.7% and 40.8%) respectively, and drowsiness (64.4% and 53.7%) respectively. After the second dose were fever (26.8% and 55.2) respectively, nausea (4.8% and 18%) respectively, diarrhea (0.5% and 5%) respectively, headache (27.3 and 44.8%) respectively and allergic reaction or skin rash (1% and 6%) respectively. After the first and second dose, participants with the AstraZeneca vaccine were most likely to get infected by COVID-19 (6.3% and 4.3%), respectively.

Conclusion: Both AstraZeneca and Moderna vaccines' most common side effects were mild-moderate such as fever, sore arm, headache, drowsiness, and nausea. Several risk factors contributed to the side effects, such as younger age (median: 22), and female participants, and non-overweight BMI (median: 21.8).

Downloads

Download data is not yet available.

References

Ciotti M, Ciccozzi M, Terrinoni A, Jiang WC, Wang CB, Bernardini S. The COVID-19 pandemic. Crit Rev Clin Lab Sci. 2020;57(6):365-88. doi: 10.1080/10408363.2020.1783198, PMID 32645276.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9. doi: 10.1001/jama.2020.1585, PMID 32031570.

Ramatillah DL, Isnaini S. Treatment profiles and clinical outcomes of COVID-19 patients at private hospital in Jakarta. PLOS One. 2021;16(4):e0250147. doi: 10.1371/ journal.pone.0250147. PMID 33861777.

Ramatillah DL, Gan SH, Sulaiman SAS, Puja D, Abubakar U, Jaber AAS, Lukas S, Jusnita N. Evaluation of treatment outcome for pneumonia among pre-vaccinated COVID-19 patients with/without comorbidity in a Public Hospital in Bengkulu, Indonesia. Vaccines. 2021;9(12):1411. doi: 10.3390/vaccines9121411, PMID 34960157.

Kostoff RN, Briggs MB, Porter AL, Spandidos DA, Tsatsakis A. [Comment] COVID 19 vaccine safety. Int J Mol Med. 2020;46(5):1599-602. doi: 10.3892/ijmm.2020.4733, PMID 33000193.

Peta Sebaran | Covid19.go.id [Internet]. Available from: https://covid19.go.id/peta-sebaran. [Last accessed on 22 Dec 2021].

Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T, COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-16. doi: 10.1056/NEJMoa2035389, PMID 33378609.

Jain S, Venkataraman A, Wechsler ME, Peppas NA. Messenger RNA-based vaccines: past, present, and future directions in the context of the COVID-19 pandemic. Adv Drug Deliv Rev. 2021 Dec;179:114000. doi: 10.1016/j.addr.2021.114000.

Minor PD. Live attenuated vaccines: historical successes and current challenges. Virology. 2015;479-480:379-92. doi: 10.1016/j.virol.2015.03.032, PMID 25864107.

Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol. 2004;82(5):488-96. doi: 10.1111/j.0818-9641.2004.01272.x, PMID 15479434.

Sutter RW. Unraveling the mucosal immunity of inactivated poliovirus vaccine. J Infect Dis. 2018;217(3):344-6. doi: 10.1093/infdis/jix557, PMID 29304197.

Nascimento IP, Leite LCC. Recombinant vaccines and the development of new vaccine strategies. Braz J Med Biol Res. 2012;45(12):1102-11. doi: 10.1590/s0100-879x2012007500142, PMID 22948379.

Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Goodman AL, Green CM, Green CA, Heath PT, Hill C, Hill H, Hirsch I, Hodgson SHC, Izu A, Jackson S, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie AM, Lelliott A, Libri V, Lillie PJ, Mallory R, Mendes AVA, Milan EP, Minassian AM, McGregor A, Morrison H, Mujadidi YF, Nana A, O’Reilly PJ, Padayachee SD, Pittella A, Plested E, Pollock KM, Ramasamy MN, Rhead S, Schwarzbold AV, Singh N, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Tarrant R, Thomson EC, Torok ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, Watson MEE, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ, Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1, PMID 33306989.

Solomon Y, Eshete T, Mekasha B, Assefa W. COVID-19 vaccine: side effects after the first dose of the oxford astrazeneca vaccine among health professionals in a low-income country: Ethiopia. J Multidiscip Healthc. 2021;14:2577-85. doi: 10.2147/JMDH.S331140, PMID 34556992.

Haynes BF. A new vaccine to battle covid-19. N Engl J Med. 2021;384(5):470-1. doi: 10.1056/NEJMe2035557, PMID 33378607.

Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of pfizer/BioNTech and moderna vaccines. Eur Rev Med Pharmacol Sci. 2021;25(3):1663-9. doi: 10.26355/eurrev_202102_24877, PMID 33629336.

Ali K, Berman G, Zhou H, Deng W, Faughnan V, Coronado Voges M, Ding B, Dooley J, Girard B, Hillebrand W, Pajon R, Miller JM, Leav B, McPhee R. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. N Engl J Med. 2021;385(24):2241-51. doi: 10.1056/NEJMoa2109522, PMID 34379915.

Southeast Asia Covid-19 tracker. Center for strategic and international studies [internet]. Available from: https://www.csis.org/programs/southeast-asia-program/projects/southeast-asia-covid-19-tracker. [Last accessed on 22 Dec 2021]

Coronavirus (COVID-19) Vaccinations-statistics and research-our world in data [Internet]. Available from: https://ourworldindata.org/covid-vaccinations?country=OWID_WRL~IDN. [Last accessed on 22 Dec 2021].

Pemerintah kejar target 70% populasi indonesia mendapat vaksin-berita Terkini | Covid19.go.id [Internet]. Available from: https://covid19.go.id/p/berita/pemerintah-kejar-target-70-populasi-indonesia-mendapat-vaksin. [Last accessed on 22 Dec 2021]

Coronavirus (COVID-19)-Google News [Internet]. [cited 2021 Dec 10]. Available from: https://news.google.com/covid19/map?hl=en-ID&mid=%2Fm%2F03ryn&state=7&gl=ID&ceid=ID%3Aen. [Last accessed on 10 Dec 2021]

Side Effects of COVID-19 Vaccines [Internet]. [cited 2021 Dec 20]. Available from: https://www.who.int/news-room/feature-stories/detail/side-effects-of-covid-19-vaccines. [Last accessed on 20 Dec 2021]

Almufty HB, Mohammed SA, Abdullah AM, Merza MA. Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study. Diabetes Metab Syndr. 2021;15(5):102207. doi: 10.1016/j.dsx.2021.102207.

Kadali RAK, Janagama R, Peruru S, Gajula V, Madathala RR, Chennaiahgari N, Malayala SV. Non-life-threatening adverse effects with COVID-19 mRNA-1273 vaccine: A randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms. J Med Virol. 2021;93(7):4420-9. doi: 10.1002/jmv.26996, PMID 33822361.

What are mRNA vaccines and how do they work?: MedlinePlus Genetics [Internet]. Available from: https://medlineplus.gov/genetics/understanding/therapy/mrnavaccines/. [Last accessed on 20 Dec 2021]

How does a mRNA vaccine compare to a traditional vaccine? | Vanderbilt Institute for Infection, Immunology and Inflammation [Internet]. Available from: https://www.vumc.org/viiii/infographics/how-does-mrna-vaccine-compare-traditional-vaccine. [Last accessed on 20 Dec 2021]

Wi YM, Kim SH, Peck KR. Early adverse events between mRNA and adenovirus-vectored COVID-19 vaccines in healthcare workers. Vaccines (Basel). 2021;9(8):1-7. doi: 10.3390/vaccines9080931, PMID 34452055.

El Sahly HM, Baden LR, Essink B, Doblecki Lewis S, Martin JM, Anderson EJ, Campbell TB, Clark J, Jackson LA, Fichtenbaum CJ, Zervos M, Rankin B, Eder F, Feldman G, Kennelly C, Han Conrad L, Levin M, Neuzil KM, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Polakowski L, Mascola JR, Ledgerwood JE, Graham BS, August A, Clouting H, Deng W, Han S, Leav B, Manzo D, Pajon R, Schödel F, Tomassini JE, Zhou H, Miller J, COVE Study Group. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at the completion of blinded phase. N Engl J Med. 2021;385(19):1774-85. doi: 10.1056/NEJMoa2113017, PMID 34551225.

Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, Neuzil KM, Hahn W, Hunt J, Mulligan MJ, McEvoy C, DeJesus E, Hassman M, Little SJ, Pahud BA, Durbin A, Pickrell P, Daar ES, Bush L, Solis J, Carr QO, Oyedele T, Buchbinder S, Cowden J, Vargas SL, Guerreros Benavides A, Call R, Keefer MC, Kirkpatrick BD, Pullman J, Tong T, Brewinski Isaacs M, Benkeser D, Janes HE, Nason MC, Green JA, Kelly EJ, Maaske J, Mueller N, Shoemaker K, Takas T, Marshall RP, Pangalos MN, Villafana T, Gonzalez-Lopez A, AstraZeneca AZD1222 Clinical Study Group. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. N Engl J Med. 2021;385(25):2348-60. doi: 10.1056/NEJMoa2105290, PMID 34587382.

The ETO, Delayed D, Rash S. Receiving A, vaccine RNAM. Etter to the. 2021;29(4):262-3.

Male V. Effect of COVID-19 vaccination on menstrual periods in a retrospectively recruited cohort; 2021. p. 1-6.

Riad A, Pokorna A, Attia S, Klugarova J, Koscík M, Klugar M. Prevalence of covid-19 vaccine side effects among healthcare workers in the Czech Republic. J Clin Med. 2021;10(7):1-18. doi: 10.3390/jcm10071428, PMID 33916020.

Pfizer. BioNTech COVID-19 vaccine reactions and adverse events. CDC. Available from: https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/reactogenicity.html.

Hoffmann MA, Wieler HJ, Enders P, Buchholz HG, Plachter B. Age- and sex-graded data evaluation of vaccination reactions after initial injection of the bnt162b2 mrna vaccine in a local vaccination center in germany. Vaccines. 2021;9(8):1-10. doi: 10.3390/vaccines9080911, PMID 34452036.

Nagelkerken L, Hertogh‐Huijbregts A, Dobber R, Drager A. Age‐related changes in lymphokine production related to a decreased number of CD45RBhi CD4+T cells. Eur J Immunol. 1991;21(2):273-81. doi: 10.1002/eji.1830210206, PMID 1671835.

Potluri T, Fink AL, Sylvia KE, Dhakal S, Vermillion MS, Vom Steeg L. Age-associated changes in the impact of sex steroids on influenza vaccine responses in males and females. NPJ Vaccines. 2019;4(1):29. doi: 10.1038/s41541-019-0124-6, PMID 31312529.

Iguacel I, Maldonado AL, Ruiz-cabello AL, Casaus M. Association between COVID-19 vaccine side effects and body mass index in. Spain; 2021. p. 1-12.

Watanabe M, Balena A, Tuccinardi D, Tozzi R, Risi R, Masi D, Caputi A, Rossetti R, Spoltore ME, Filippi V, Gangitano E, Manfrini S, Mariani S, Lubrano C, Lenzi A, Mastroianni C, Gnessi L. Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine. Diabetes Metab Res Rev. 2022;38(1) (Apr):e3465. doi: 10.1002/dmrr.3465, PMID 33955644.

Wei J, Stoesser N, Matthews PC, Ayoubkhani D, Studley R, Bell I, Bell JI, Newton JN, Farrar J, Diamond I, Rourke E, Howarth A, Marsden BD, Hoosdally S, Jones EY, Stuart DI, Crook DW, Peto TEA, Pouwels KB, Eyre DW, Walker AS, COVID-19 Infection Survey team. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. Nat Microbiol. 2021;6(9):1140-9. doi: 10.1038/s41564-021-00947-3, PMID 34290390.

Tang Y, Chen Y, Feng H, Zhu C, Tong M, Chen Q. Is body mass index associated with irregular menstruation: a questionnaire study? BMC Womens Health. 2020;20(1):226. doi: 10.1186/s12905-020-01085-4, PMID 33032583.